Tempus AI, Inc. (NASDAQ: TEM) is experiencing a rise in its stock price after acquiring Paige, an AI company specializing in digital pathology. Tempus, a technology company dedicated to advancing precision medicine through AI, aims to expand its dataset, technical team, and establish a strong presence in digital pathology through this acquisition. The deal involves a consideration of $81.25 million, primarily paid in Tempus common stock, along with Tempus taking over Paige's remaining commitment under its current Microsoft Azure cloud services agreement. Paige, founded in 2017, has successfully developed and implemented various AI applications, including the first FDA-cleared AI application in pathology. This strategic move indicates Tempus' commitment to growth and innovation in the healthcare technology sector.